Dhruva Mishra's Contact Details

Dhruva Mishra's Company Details

OncoMatrix Biotech

Houston, Texas, United States • 1 Employees
Research

OncoMatrix Biotech strives to improve and prolong the quality of life of cancer patients and transform anticancer drug development. We provide next-generation drug and biomarker screening services on three critical Cs of cancer metastases and tumor relapse:1. Circulating Tumor Cells (CTCs)/metastatic initiating cells (MICs)2. Cell-free tumor DNA (ctDNA)3. Circulating tumor metabolitesMetastasis causes >90% of cancer deaths. More than 95% of oncology drugs fail to translate preclinical drug candidates into clinical success. The majority of physicians and scientists believe that this discordance is primarily attributed to the lack of testing the efficacy of candidate drugs on Circulating Tumor Cells (CTCs) in the early development phase. Instead of using traditional cell line cultures on the artificial matrix, OncoMatrix Biotech leverages its innovative platform technology capabilities. Our platform is physiologically relevant to human cancers to screen the drug efficacy on CTCs, metastatic lesions, primary tumors and discover personalized liquid biopsy biomarkers.